Comment on “S GATA3 Immunohistochemical Staining in Classical Hodgkin Lymphoma and Its Diagnostic Utility in Differential Diagnosis”

The publication on "GATA3 Immunohistochemical Staining in Classical Hodgkin Lymphoma and Its Diagnostic Utility in Differential Diagnosis [1]" is hereby discussed.This study is unique in its ability to assess the potential of GATA3, a transcription factor commonly used in the classification of epithelial tumors, as a biomarker for distinguishing classical Hodgkin lymphoma (CHL) from other lymphomas, particularly in cases where aberrant antigen expression in CHL is frequently a major obstacle to diagnosis.As a result, efforts to identify new markers that can help differentiate are critical for accurate and timely diagnosis.However, the study used a cross-sectional retrospective design, which, although somewhat suitable for the analysis of marker expression in tissues, has some limitations that should be mentioned, such as the lack of standardization of IHC and the variety of methods for evaluating GATA3 staining results, which may lead to inter-observer variability.The definition of what "nuclear expression" is considered positive (e.g., minimum cell count or intensity level), may affect the accuracy of the conclusion.And there is no mention of technical controls, such as the use of internal positive controls in each biopsy.Statistically, using p-value alone to compare various groups, while it can find differences, lacks additional clinical indicators, such as sensitivity, specificity, PPV, NPV, or AUC, which are required for the practical application of this marker in pathological diagnosis.Furthermore, the study's findings show that GATA3 is ineffective in distinguishing CHL from ALK-negative anaplastic large-cell lymphoma (ALCL) and mediastinal gray-zone lymphoma, which is a significant limitation because these two lymphomas are frequently included in the complex differential diagnosis with CHL, particularly when the biopsy is small or has few components.Questions for further debate include: (1) Can GATA3 be used in conjunction with other markers, such as PAX5, CD30, or LMP1, to improve the accuracy of CHL diagnosis?(2) Is it possible to construct a grading system or AI-based histopathology that includes GATA3 in the model?(3) Does GATA3 expression have a direct biological function in the pathogenesis of CHL, or is it simply a co-marker?And (4) In circumstances where biopsy has limits, such as core needle biopsy, what other procedures or markers should be employed to improve diagnosis?Future research should include investigations on other lymphoma subtypes, as well as trials in real-world settings, particularly in cases when diagnosis is challenging.In addition, multivariate analysis should be performed to see if GATA3 remains significant after correcting for other variables such patient age, concomitant clinical characteristics, and EBV status.This study discovered that GATA3 was more highly expressed in EBV-negative CHL, which could reflect different genetic regulatory mechanisms amongst CHL subtypes.Finally, this study adds to the development of a new tool for distinguishing comparable lymphomas, particularly CHL, which, despite the presence of unique markers, sometimes causes uncertainty in interpretation.However, GATA3's efficacy remains restricted in some lymphomas, making it unsuitable for situations involving tiny biopsies.As a result, integrating GATA3 with other markers and assessing it against clinical criteria will be a more appropriate method for reliable diagnosis in the future.